NDAORALFOR SUSPENSION
Approved
Oct 2009
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
12
Data completeness
4/8 — Partial
WELCHOL (colesevelam hydrochloride) by Ichnos Glenmark Innovation is : colesevelam hydrochloride, the active pharmaceutical ingredient in welchol, is a non-absorbed, lipid-lowering polymer that binds bile acids in the intestine, impeding their reabsorption. Approved for type 2 diabetes, hypercholesterolemia, familial hypercholesterolemia. First approved in 2009.
Drug data last refreshed 20h ago
Mechanism of Action
: Colesevelam hydrochloride, the active pharmaceutical ingredient in WELCHOL, is a non-absorbed, lipid-lowering polymer that binds bile acids in the intestine, impeding their reabsorption. As the bile acid pool becomes depleted, the hepatic enzyme, cholesterol 7-α-hydroxylase, is upregulated, which…
Indications (3)
Worked on WELCHOL at Ichnos Glenmark Innovation? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.